申请人:Taisho Pharmaceutical Co., Ltd.
公开号:US07932259B2
公开(公告)日:2011-04-26
An object of the present invention is to provide an antagonist against CRF receptors which is effective as a therapeutic or prophylactic agent for diseases in which CRF is considered to be involved, such as depression, anxiety, Alzheimer's disease, Parkinson's disease, Huntington's chorea, eating disorder, hypertension, gastric diseases, drug dependence, epilepsy, cerebral infarction, cerebral ischemia, cerebral edema, cephalic external wound, inflammation, immunity-related diseases, alopecia, irritable bowel syndrome, sleep disorders, epilepsy, dermatitides, schizophrenia, etc. This problem can be solved with a pyrrolopyrimidine or pyrrolopyridine derivative substituted with a cyclic amino group represented by formula [I] below which has a high affinity for CRF receptors and is effective against diseases in which CRF is considered to be involved.
本发明的目的是提供一种CRF受体拮抗剂,作为治疗或预防CRF参与的疾病的药物,例如抑郁症、焦虑症、阿尔茨海默病、帕金森病、亨廷顿舞蹈症、进食障碍、高血压、胃病、药物依赖、癫痫、脑梗塞、脑缺血、脑水肿、头部外伤、炎症、免疫相关疾病、脱发、肠易激综合征、睡眠障碍、皮炎、精神分裂症等。这个问题可以通过一种具有高亲和力的代表公式[I]的含有环状氨基团的吡咯吡嘧啶或吡咯吡啶衍生物来解决,该衍生物对CRF受体有效,对CRF参与的疾病也有效。